Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and fiscal year ended March 31, 2017
Filing Date: May 15, 2017
Announcement Date: May 12, 2017
This filing discloses the results of operations and financial condition for the quarter and year ended March 31, 2017. The company issued a press release under International Financial Reporting Standards (IFRS) and made available audited standalone and consolidated financial results under Indian Accounting Standards (Ind AS) on its website.
Key Financial Metrics
The provided filing text serves as a cover document referencing attached exhibits (Exhibits 99.1, 99.2, and 99.3) containing the detailed financial data. The text itself does not provide specific numerical values for:
- Revenue
- Profit (Net Income)
- Cash Flow
- Margins
- Debt Levels
- Liquidity Ratios
Note: Specific financial figures are not present in the cover letter text; they are contained within the referenced press release and audited reports.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It only confirms that results for the quarter and year ended March 31, 2017, have been announced and attached as exhibits.
Guidance, Outlook, and Risks
The provided text does not contain management commentary, forward-looking guidance, specific risk factors, contingencies, or unusual items. These details are expected to be found in the attached press release (Exhibit 99.1) and the audited financial statements (Exhibits 99.2 and 99.3).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, profit, and margin figures under IFRS.
- Examine Exhibits 99.2 and 99.3 for audited standalone and consolidated results under Ind AS to verify accounting standard differences.
- Check the company website (www.drreddys.com) for the full text of the May 12, 2017 announcement regarding management commentary and outlook.
- Verify the specific impact of any regulatory or operational events mentioned in the full press release, as the cover letter does not list them.